{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:43:55Z","timestamp":1788918235060,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To provide a comprehensive review of new and emerging literature on B cells and tertiary lymphoid structures (TLS) in urothelial cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The presence of certain subsets of B cells and TLS in MIBC are associated with improved outcomes and response to immunotherapy. However, the role in NMIBC is less clear. TLS in NMIBC is likely associated with more aggressive disease but may also be associated with improved outcomes to intravesical BCG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review outlines an emerging potential biomarker (TLS) for predictive and prognostic outcomes for patients with urothelial cancer receiving either intravesical BCG or systemic immunotherapy. B cells play a complex role in the tumor immune microenvironment and can be either anti- or pro-tumor. Activated B cells form TLS which lead to a robust response to immunotherapy. This has led some investigators to attempt therapeutic manipulation to induce TLS in otherwise immunologically \u201ccold\u201d tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11934-025-01314-z","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T01:11:05Z","timestamp":1766970665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Andrew","family":"Penunuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliyahu","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Katims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"19","key":"1314_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391(19):1773\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2408154.","journal-title":"N Engl J Med"},{"issue":"6","key":"1314_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi A, Roumiguie M, Kamat AM, Shore ND, Boormans JL, Esen AA, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;25(6):720\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(24)00178-5.","journal-title":"Lancet Oncol"},{"key":"1314_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01897-5","author":"M De Santis","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H, Krawczy\u0144ski M, Seyitkuliev A, Novikov A, et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)01897-5.","journal-title":"Lancet"},{"issue":"8","key":"1314_CR4","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025;31(8):2806\u201314. https:\/\/doi.org\/10.1038\/s41591-025-03738-z.","journal-title":"Nat Med"},{"key":"1314_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-3-030-59038-3_17","volume":"1296","author":"K Hatogai","year":"2020","unstructured":"Hatogai K, Sweis RF. The tumor microenvironment of bladder cancer. Adv Exp Med Biol. 2020;1296:275\u201390. https:\/\/doi.org\/10.1007\/978-3-030-59038-3_17.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"1314_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006.","journal-title":"Eur Urol"},{"key":"1314_CR7","doi-asserted-by":"publisher","first-page":"1546160","DOI":"10.3389\/fonc.2025.1546160","volume":"15","author":"G Attanasio","year":"2025","unstructured":"Attanasio G, Failla M, Poidomani S, Buzzanca T, Salzano S, Zizzo M, et al. Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer. Front Oncol. 2025;15:1546160. https:\/\/doi.org\/10.3389\/fonc.2025.1546160.","journal-title":"Front Oncol"},{"issue":"10","key":"1314_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.urolonc.2022.05.013","volume":"41","author":"C Chu","year":"2023","unstructured":"Chu C, Pietzak E. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: invited review for special issue seminar: treatment advances and molecular biology insights in urothelial carcinoma. Urol Oncol. 2023;41(10):398\u2013409. https:\/\/doi.org\/10.1016\/j.urolonc.2022.05.013.","journal-title":"Urol Oncol"},{"key":"1314_CR9","doi-asserted-by":"publisher","first-page":"1235884","DOI":"10.3389\/fimmu.2023.1235884","volume":"14","author":"J van Dorp","year":"2023","unstructured":"van Dorp J, van der Heijden MS. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Front Immunol. 2023;14:1235884. https:\/\/doi.org\/10.3389\/fimmu.2023.1235884.","journal-title":"Front Immunol"},{"issue":"3","key":"1314_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.eururo.2023.11.008","volume":"85","author":"W Beckabir","year":"2024","unstructured":"Beckabir W, Wobker SE, Damrauer JS, Midkiff B, la De Cruz G, Makarov V, et al. Spatial relationships in the tumor microenvironment demonstrate association with pathologic response to neoadjuvant chemoimmunotherapy in muscle-invasive bladder cancer. Eur Urol. 2024;85(3):242\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2023.11.008.","journal-title":"Eur Urol"},{"issue":"4","key":"1314_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/cac2.12491","volume":"44","author":"X Wang","year":"2024","unstructured":"Wang X, Juncker-Jensen A, Huang G, Nagy ML, Lu X, Cheng L. Spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in bladder cancer and prognostic potential for anti-PD-L1 immunotherapy. Cancer Commun. 2024;44(4):499\u2013503. https:\/\/doi.org\/10.1002\/cac2.12491.","journal-title":"Cancer Commun"},{"issue":"6","key":"1314_CR12","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509\u201321. https:\/\/doi.org\/10.1002\/jcp.27782.","journal-title":"J Cell Physiol"},{"issue":"7","key":"1314_CR13","doi-asserted-by":"publisher","first-page":"e2410998","DOI":"10.1002\/advs.202410998","volume":"12","author":"J Lin","year":"2025","unstructured":"Lin J, Jiang S, Chen B, Du Y, Qin C, Song Y, et al. Tertiary lymphoid structures are linked to enhanced antitumor immunity and better prognosis in muscle-invasive bladder cancer. Adv Sci. 2025;12(7):e2410998. https:\/\/doi.org\/10.1002\/advs.202410998.","journal-title":"Adv Sci"},{"key":"1314_CR14","doi-asserted-by":"publisher","first-page":"625667","DOI":"10.3389\/fimmu.2021.625667","volume":"12","author":"J Lee","year":"2021","unstructured":"Lee J, Lozano-Ruiz B, Yang FM, Fan DD, Shen L, Gonzalez-Navajas JM. The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy. Front Immunol. 2021;12:625667. https:\/\/doi.org\/10.3389\/fimmu.2021.625667.","journal-title":"Front Immunol"},{"issue":"9","key":"1314_CR15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-20-0949","volume":"9","author":"K Wennhold","year":"2021","unstructured":"Wennhold K, Thelen M, Lehmann J, Schran S, Preugszat E, Garcia-Marquez M, et al. CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses. Cancer Immunol Res. 2021;9(9):1098\u2013108. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0949.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1314_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12967-024-04860-1","volume":"22","author":"H Yuan","year":"2024","unstructured":"Yuan H, Mao X, Yan Y, Huang R, Zhang Q, Zeng Y, et al. Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer. J Transl Med. 2024;22(1):48. https:\/\/doi.org\/10.1186\/s12967-024-04860-1.","journal-title":"J Transl Med"},{"issue":"10","key":"1314_CR17","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","volume":"5","author":"TC Bruno","year":"2017","unstructured":"Bruno TC, Ebner PJ, Moore BL, Squalls OG, Waugh KA, Eruslanov EB, et al. Antigen-presenting intratumoral B cells affect CD4(+) TIL phenotypes in non-small cell lung cancer patients. Cancer Immunol Res. 2017;5(10):898\u2013907. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0075.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"1314_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautes-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441\u201357. https:\/\/doi.org\/10.1038\/s41571-022-00619-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"1314_CR19","doi-asserted-by":"publisher","first-page":"850998","DOI":"10.3389\/fimmu.2022.850998","volume":"13","author":"Z Pan","year":"2022","unstructured":"Pan Z, Zhu T, Liu Y, Zhang N. Role of the CXCL13\/CXCR5 axis in autoimmune diseases. Front Immunol. 2022;13:850998. https:\/\/doi.org\/10.3389\/fimmu.2022.850998.","journal-title":"Front Immunol"},{"issue":"5","key":"1314_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","volume":"20","author":"GV Sharonov","year":"2020","unstructured":"Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020;20(5):294\u2013307. https:\/\/doi.org\/10.1038\/s41577-019-0257-x.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1314_CR21","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","volume":"71","author":"PB Olkhanud","year":"2011","unstructured":"Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011;71(10):3505\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4316.","journal-title":"Cancer Res"},{"issue":"4","key":"1314_CR22","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.clgc.2025.102351","volume":"23","author":"KD Raja","year":"2025","unstructured":"Raja KD, Singh A, Akhtar S, Singh P, Seth A, Kaushal S, et al. Phenotypic diversity of immunosuppressive B cells associated in urothelial carcinoma of the bladder. Clin Genitourin Cancer. 2025;23(4):102351. https:\/\/doi.org\/10.1016\/j.clgc.2025.102351.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1314_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13046-024-03017-8","volume":"43","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zhou R, Zhu Y, Deng S, Muhuitijiang B, Li C, et al. Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity. J Exp Clin Cancer Res. 2024;43(1):101. https:\/\/doi.org\/10.1186\/s13046-024-03017-8.","journal-title":"J Exp Clin Cancer Res"},{"key":"1314_CR24","doi-asserted-by":"publisher","first-page":"1616904","DOI":"10.3389\/fonc.2025.1616904","volume":"15","author":"C Liu","year":"2025","unstructured":"Liu C, Cao J. The pivotal role of tertiary lymphoid structures in the tumor immune microenvironment. Front Oncol. 2025;15:1616904. https:\/\/doi.org\/10.3389\/fonc.2025.1616904.","journal-title":"Front Oncol"},{"issue":"9","key":"1314_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24(9):629\u201346. https:\/\/doi.org\/10.1038\/s41568-024-00728-0.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1314_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1314_CR27","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1172\/JCI67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873\u201392. https:\/\/doi.org\/10.1172\/JCI67428.","journal-title":"J Clin Invest"},{"issue":"8","key":"1314_CR28","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","volume":"20","author":"G Di Caro","year":"2014","unstructured":"Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res. 2014;20(8):2147\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2590.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1314_CR29","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/ni.3290","volume":"16","author":"S Finkin","year":"2015","unstructured":"Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16(12):1235\u201344. https:\/\/doi.org\/10.1038\/ni.3290.","journal-title":"Nat Immunol"},{"issue":"3","key":"1314_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8 + T cells. Cancer Res. 2014;74(3):705\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1342.","journal-title":"Cancer Res"},{"issue":"9","key":"1314_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","volume":"56","author":"A Ladanyi","year":"2007","unstructured":"Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56(9):1459\u201369. https:\/\/doi.org\/10.1007\/s00262-007-0286-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"1314_CR32","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","volume":"22","author":"DR Kroeger","year":"2016","unstructured":"Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 2016;22(12):3005\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2762.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1314_CR33","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/bjc.2015.145","volume":"112","author":"N Hiraoka","year":"2015","unstructured":"Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015;112(11):1782\u201390. https:\/\/doi.org\/10.1038\/bjc.2015.145.","journal-title":"Br J Cancer"},{"issue":"2","key":"1314_CR34","doi-asserted-by":"publisher","first-page":"e1054598","DOI":"10.1080\/2162402X.2015.1054598","volume":"5","author":"A Hennequin","year":"2016","unstructured":"Hennequin A, Derangere V, Boidot R, Apetoh L, Vincent J, Orry D. <article-title update=\"added\">Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology. 2016;5(2):e1054598. https:\/\/doi.org\/10.1080\/2162402X.2015.1054598.","journal-title":"Oncoimmunology"},{"key":"1314_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003883","author":"T Masuda","year":"2022","unstructured":"Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T, et al. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003883.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1314_CR36","doi-asserted-by":"publisher","first-page":"e45013","DOI":"10.1016\/j.urolonc.2024.06.010","volume":"42","author":"F Yilmaz","year":"2024","unstructured":"Yilmaz F, Sagir S. Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method? Urol Oncol. 2024;42(12):e45013\u201322. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.010.","journal-title":"Urol Oncol"},{"issue":"2","key":"1314_CR37","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1093\/oncolo\/oyad283","volume":"29","author":"G Ma","year":"2024","unstructured":"Ma G, Jia H, Zhang G, Liang Y, Dong X, Fu G, et al. Presence, subtypes, and prognostic significance of tertiary lymphoid structures in urothelial carcinoma of the bladder. Oncologist. 2024;29(2):e248\u201358. https:\/\/doi.org\/10.1093\/oncolo\/oyad283.","journal-title":"Oncologist"},{"issue":"4","key":"1314_CR38","doi-asserted-by":"publisher","first-page":"268 e9","DOI":"10.1016\/j.urolonc.2024.11.017","volume":"43","author":"OY Balcik","year":"2025","unstructured":"Balcik OY, Yilmaz F. FOXP3\/TLS; a prognostic marker in patients with bladder carcinoma without muscle invasion. Urol Oncol. 2025;43(4):268 e9\u2013e26. https:\/\/doi.org\/10.1016\/j.urolonc.2024.11.017.","journal-title":"Urol Oncol"},{"issue":"10","key":"1314_CR39","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1158\/2326-6066.CIR-23-1114","volume":"12","author":"P Yolmo","year":"2024","unstructured":"Yolmo P, Rahimi S, Chenard S, Conseil G, Jenkins D, Sachdeva K, et al. Atypical B cells promote cancer progression and poor response to Bacillus Calmette-Guerin in non-muscle invasive bladder cancer. Cancer Immunol Res. 2024;12(10):1320\u201339. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-1114.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1314_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00262-018-2250-9","volume":"68","author":"Q Jiang","year":"2019","unstructured":"Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L. <article-title update=\"added\">CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2019;68(1):45\u201356. https:\/\/doi.org\/10.1007\/s00262-018-2250-9.","journal-title":"Cancer Immunol Immunother"},{"key":"1314_CR41","doi-asserted-by":"publisher","first-page":"793992","DOI":"10.3389\/fimmu.2021.793992","volume":"12","author":"F Pagliarulo","year":"2021","unstructured":"Pagliarulo F, Cheng PF, Brugger L, van Dijk N, van den Heijden M, Levesque MP, et al. Molecular, immunological, and clinical features associated with lymphoid neogenesis in muscle invasive bladder cancer. Front Immunol. 2021;12:793992. https:\/\/doi.org\/10.3389\/fimmu.2021.793992.","journal-title":"Front Immunol"},{"issue":"3","key":"1314_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.euo.2021.07.003","volume":"5","author":"AK Aragaki","year":"2022","unstructured":"Aragaki AK, Jing Y, Hoffman-Censits J, Choi W, Hahn NM, Trock BJ, et al. Gender-specific stratification of survival following immune checkpoint inhibitor therapy based on intratumoral expression of a B cell gene signature. Eur Urol Oncol. 2022;5(3):338. https:\/\/doi.org\/10.1016\/j.euo.2021.07.003.","journal-title":"Eur Urol Oncol"},{"key":"1314_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2021.01.036","volume":"148","author":"CS Groeneveld","year":"2021","unstructured":"Groeneveld CS, Fontugne J, Cabel L, Bernard-Pierrot I, Radvanyi F, Allory Y, et al. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer. 2021;148:181\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.036.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1314_CR44","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/s41467-024-46450-1","volume":"15","author":"A Gil-Jimenez","year":"2024","unstructured":"Gil-Jimenez A, van Dijk N, Vos JL, Lubeck Y, van Montfoort ML, Peters D, et al. Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors. Nat Commun. 2024;15(1):2538. https:\/\/doi.org\/10.1038\/s41467-024-46450-1.","journal-title":"Nat Commun"},{"issue":"1","key":"1314_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/BLC-189029","volume":"4","author":"M Koti","year":"2018","unstructured":"Koti M, Xu AS, Ren KYM, Visram K, Ren R, Berman DM, et al. Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. Bladder Cancer. 2018;4(1):137. https:\/\/doi.org\/10.3233\/BLC-189029.","journal-title":"Bladder Cancer"},{"issue":"9","key":"1314_CR46","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/modpathol.2017.43","volume":"30","author":"L Buisseret","year":"2017","unstructured":"Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, et al. Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod Pathol. 2017;30(9):1204\u201312. https:\/\/doi.org\/10.1038\/modpathol.2017.43.","journal-title":"Mod Pathol"},{"issue":"1","key":"1314_CR47","doi-asserted-by":"publisher","first-page":"e2252553","DOI":"10.1001\/jamanetworkopen.2022.52553","volume":"6","author":"Z Li","year":"2023","unstructured":"Li Z, Jiang Y, Li B, Han Z, Shen J, Xia Y, et al. Development and validation of a machine learning model for detection and classification of tertiary lymphoid structures in gastrointestinal cancers. JAMA Netw Open. 2023;6(1):e2252553. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.52553.","journal-title":"JAMA Netw Open"},{"key":"1314_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157215","author":"M Ukita","year":"2022","unstructured":"Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A, et al. CXCL13-producing CD4 + T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.157215.","journal-title":"JCI Insight"},{"issue":"5","key":"1314_CR49","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jcmgh.2021.06.023","volume":"12","author":"FR Delvecchio","year":"2021","unstructured":"Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, et al. Pancreatic cancer chemotherapy is potentiated by induction of tertiary lymphoid structures in mice. Cell Mol Gastroenterol Hepatol. 2021;12(5):1543\u201365. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.06.023.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1314_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1346","author":"CS Garris","year":"2021","unstructured":"Garris CS, Wong JL, Ravetch JV, Knorr DA. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Sci Transl Med. 2021. https:\/\/doi.org\/10.1126\/scitranslmed.abd1346.","journal-title":"Sci Transl Med"},{"key":"1314_CR51","doi-asserted-by":"publisher","unstructured":"Osorio JC, Knorr DA, Weitzenfeld P, Blanchard L, Yao N, Baez M et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. 2025;43(10):1902-16.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.07.013","DOI":"10.1016\/j.ccell.2025.07.013"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01314-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-025-01314-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01314-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T01:11:06Z","timestamp":1766970666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-025-01314-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1314"],"URL":"https:\/\/doi.org\/10.1007\/s11934-025-01314-z","relation":{},"ISSN":["1534-6285"],"issn-type":[{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}